Inhibition of Angiogenesis In Vitro by Chebulagic Acid: A COX-LOX Dual Inhibitor

Area of Science:

• Biochemistry
• Pharmacology
• Oncology

Background:

• Angiogenesis, or new blood vessel formation, is vital for cancer growth and metastasis.
• Both internal and external factors regulate angiogenesis, making it a therapeutic target.
• Natural compounds are being investigated for their potential to modulate angiogenesis.

Purpose of the Study:

• To investigate the anti-angiogenic potential of chebulagic acid, a dual COX-LOX inhibitor from Terminalia chebula.
• To understand the molecular mechanisms underlying chebulagic acid's effect on angiogenesis.

Main Methods:

• Utilized rat aortic ring assays to assess sprouting.
• Employed human umbilical vein endothelial cells (HUVECs) for in vitro analysis.
• Measured biochemical markers including CD31, E-selectin, and vascular endothelial growth factor (VEGF).

Main Results:

• Chebulagic acid demonstrated significant anti-angiogenic activity in both model systems.
• Reduced sprouting was observed in rat aortic rings.
• Decreased levels of CD31, E-selectin, and VEGF were noted in HUVECs treated with chebulagic acid.

Conclusions:

• Chebulagic acid exhibits a potent anti-angiogenic effect.
• The compound downregulates key markers of angiogenesis in endothelial cells.
• Chebulagic acid's mechanism involves modulating VE-cadherin/β-catenin signaling, suggesting therapeutic potential.